Bioengineered skin substitutes present an efficient alternative in substituting donor skin grafts and are emerging therapeutic tools with a wide range of application areas. Acting as a temporary protective cover of the wound bed, skin substitutes deliver both epidermal and dermal components required to achieve functional wound closure. The available products in the market can be classified on the basis of anatomical structure, duration of cover, skin substitutes composition, and biomaterial type.
Synthetic skin substitutes are designed primarily to function as barriers to fluid loss and microbial contamination and are usually made up of acellular materials. Alternately, natural skin substitutes are mainly cultured allogenic or autologous cell suspensions or sheets that are often used along with a dermal matrix.
Bioengineered skin substitutes are the upcoming alternatives to the traditional wound-healing strategies and tissue regeneration, designed to treat a wide range of acute and chronic wounds. These products remove dead tissues, foreign bodies, bacteria from the affected area, as well as reduce inflammation, encourage healing, and protect the wounded area. Chronic wound conditions such as pressure ulcers and diabetic foot ulcers are some of the diseases that are non-healing in nature and are highly challenging to manage. However, with the help of synthetic skin substitutes, there is a change to manage such conditions.
Bioengineered skin substitutes market is expected to reach $4.33 billion by 2030. Some of the key factors driving the skin and dermal substitutes market include the increasing aging population, which is putting a strain on the global healthcare industry, the increasing prevalence of chronic diseases such as neurodegenerative disorders, diabetes, and obesity, changing reimbursement policies, and the increasing private insurance coverage, which is willing to pay for these new treatments.